Supriya Lifescience Q4 FY26 Revenue Surges 50% YoY to ₹276.53 Crore
Supriya Lifescience reported Q4 FY26 revenue of ₹276.53 crore, a 50.2% YoY increase. FY26 revenue reached ₹827.87 crore, up 18.9% YoY. PAT for Q4 FY26 was ₹74.23 crore and for FY26 was ₹209.12 crore. The anesthetic segment drove growth, contributing 54% of FY26 revenues.
The announcement includes significant financial performance metrics for the quarter and full year, demonstrating substantial revenue growth and improved profitability, which are key indicators for investors.
The company reported strong year-over-year growth in revenue and PAT for both the quarter and the full fiscal year, along with positive commentary from the Executive Chairman about future prospects and strategic initiatives.
Supriya Lifescience Ltd. announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a significant year-over-year growth in revenue for Q4 FY26, which surged by 50.2% to ₹276.53 crore, up from ₹184.11 crore in Q4 FY25.
EBITDA for the fourth quarter stood at ₹97.62 crore, with an EBITDA margin of 35.3%, compared to ₹67.58 crore and a 36.7% margin in the prior year's quarter. Profit After Tax (PAT) for Q4 FY26 was ₹74.23 crore, an increase from ₹50.37 crore in Q4 FY25, though the PAT margin saw a slight decrease to 26.8% from 27.4%.
For the full fiscal year FY26, revenue from operations grew by 18.9% YoY to ₹827.87 crore, compared to ₹696.48 crore in FY25. EBITDA for FY26 was ₹294.05 crore, a 12.8% increase from FY25's ₹260.79 crore, with an EBITDA margin of 35.5%. PAT for FY26 increased by 11.3% YoY to ₹209.12 crore, from ₹187.96 crore in FY25, with a PAT margin of 25.3%.
The anesthetic segment was the primary growth driver, contributing 54% of total revenues, up from 49% in FY25. The vitamins segment's contribution also improved to 12%. Europe remained the largest market, accounting for 40% of FY26 revenues, followed by Asia (33%) and LATAM (20%). Export contribution was strong at approximately 82% of FY26 revenues.
The company commercialized its Liquid Anesthetic product and saw traction in new launches across cardiovascular and ADHD segments. Capacity utilization improved to 74% in FY26 from 70% in FY25. Strategic land acquisitions were made for expansion, and the Ambernath formulation facility commissioned five finished dosage manufacturing lines.
Dr. Satish Wagh, Executive Chairman, stated that the strong performance reflects steady demand, healthy traction in regulated markets, and operational focus. He highlighted capacity utilization, market expansion, and new product contributions as key growth drivers. The company is well-positioned for sustainable long-term growth.
What to do with a filing like this
Supriya Lifescience Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Supriya Lifescience Limited. Read the original for the full detail.